{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:58:53Z","timestamp":1785481133237,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has substantially improved outcomes in refractory hematologic malignancies but may cause cardiovascular complications, particularly in the context of cytokine release syndrome (CRS). Real-world data on incidence, severity, and prognostic relevance of cancer therapy\u2013related cardiovascular toxicity (CTR-CVT) defined by the 2022 ESC cardio-oncology guidelines remain in the context of CAR-T cell therapy limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center study includes 104 patients treated with CAR T-cells between 09\/2019 and 02\/2024 for acute lymphoblastic leukemia, non-Hodgkin lymphoma and multiple myeloma. The primary endpoint was new-onset CTR-CVT during hospital stay, defined as cancer therapy\u2013related cardiac dysfunction (CTRCD), arrhythmia, myocardial infarction, cardiogenic shock, or cardiovascular death. Clinical characteristics, biomarkers, echocardiographic parameters, CRS\/ICANS severity, and survival outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-two patients (50%) met criteria for CTR-CVT, predominantly due to asymptomatic biomarker elevation. CTRCD occurred in 48.1%, whereas clinically significant events were rare: three patients developed symptomatic CTRCD, one experienced cardiogenic shock, and no myocardial infarctions or cardiovascular deaths were observed. Cardiovascular events occurred early and were associated with higher-grade CRS and ICANS, as well as elevated inflammatory markers. Reduced baseline left ventricular ejection fraction, elevated systolic pulmonary artery pressure, impaired performance status, and beta-blocker use were associated with increased CTR-CVT risk. Survival was numerically lower in patients with CTR-CVT but did not reach statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although half of patients fulfilled ESC criteria for CTR-CVT, clinically relevant cardiac events after CAR T-cell therapy were uncommon. These findings suggest potential overclassification driven by biomarker elevations and underscore the importance of emphasizing clinical relevance when assessing cardiotoxicity in CAR T-cell recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-026-00544-5","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:46:45Z","timestamp":1785415605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer treatment-related cardiovascular toxicity according to the ESC definition in patients receiving CAR T-cell therapy"],"prefix":"10.1186","volume":"12","author":[{"given":"Jakob Christoph","family":"Voran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Dempfle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Nakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guranda","family":"Chitadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Schub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catrin","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatim","family":"Seoudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derk","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia D","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"544_CR1","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA. 2024;332:1924\u201335. https:\/\/doi.org\/10.1001\/jama.2024.19462.","journal-title":"JAMA"},{"key":"544_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Richter J, Isenberg D, Roddie C. CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transpl. 2025;60:6\u20139. https:\/\/doi.org\/10.1038\/s41409-024-02429-6.","journal-title":"Bone Marrow Transpl"},{"key":"544_CR3","doi-asserted-by":"publisher","first-page":"e230622206353","DOI":"10.2174\/1573403X18666220623152350","volume":"19","author":"J Gill","year":"2023","unstructured":"Gill J. Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. Curr Cardiol Rev. 2023;19:e230622206353. https:\/\/doi.org\/10.2174\/1573403X18666220623152350.","journal-title":"Curr Cardiol Rev"},{"key":"544_CR4","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","volume":"4","author":"S Ganatra","year":"2022","unstructured":"Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A. Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer. JACC CardioOncol. 2022;4:616\u201323. https:\/\/doi.org\/10.1016\/j.jaccao.2022.07.014.","journal-title":"JACC CardioOncol"},{"key":"544_CR5","first-page":"77e1","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transpl Cell Ther. 2024;30:77e1. 77.e15.","journal-title":"Transpl Cell Ther"},{"key":"544_CR6","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1182\/bloodadvances.2025016778","volume":"9","author":"X Desch\u00eanes-Simard","year":"2025","unstructured":"Desch\u00eanes-Simard X, Bromberg M, Devlin SM, Gonen M, Beyar-Katz O, Ip A, Marcus R, Avigdor A, Ballweg A, Rabinovich E, Alhomoud M, Rivas Delgado A, Corona De Lapuerta M, De Luna A, Palomba ML, Shah GL, Lin R, Boardman AP, Falchi L, Lue J, Salles G, Perales M-A, Shouval R, Dahi PB, Scordo M. Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma. Blood Adv. 2025;9:5571\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2025016778.","journal-title":"Blood Adv"},{"key":"544_CR7","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"key":"544_CR8","doi-asserted-by":"publisher","first-page":"102504","DOI":"10.1016\/j.eclinm.2024.102504","volume":"69","author":"F Korell","year":"2024","unstructured":"Korell F, Entenmann L, Romann S, Giannitsis E, Schmitt A, M\u00fcller-Tidow C, Frey N, Dreger P, Schmitt M, Lehmann LH. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. EClinicalMedicine. 2024;69:102504. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102504.","journal-title":"EClinicalMedicine"},{"key":"544_CR9","doi-asserted-by":"publisher","first-page":"e2437222","DOI":"10.1001\/jamanetworkopen.2024.37222","volume":"7","author":"D Koeckerling","year":"2024","unstructured":"Koeckerling D, Reddy RK, Barker J, Eichhorn C, Divall P, Howard JP, Korell F, Schmitt M, Dreger P, Frey N, Lehmann LH. Cardiovascular Events After Chimeric Antigen Receptor T-Cell Therapy for Advanced Hematologic Malignant Neoplasms: A Meta-Analysis. JAMA Netw Open. 2024;7:e2437222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.37222.","journal-title":"JAMA Netw Open"},{"key":"544_CR10","doi-asserted-by":"crossref","unstructured":"Voran JC, Fransecky L, Seoudy H, Hecht M, M\u00fcller O, Berning P, Baden C, Versteegen T, Baldus CD, St\u00f6lzel F, Frank D, Baden D. Low cardiovascular event rates in patients treated with CAR T-cells: Real-world outcomes from two independent cohorts, 2026.","DOI":"10.1093\/eschf\/xvag132"},{"key":"544_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","volume":"5","author":"A Vasbinder","year":"2023","unstructured":"Vasbinder A, Hoeger CW, Catalan T, Anderson E, Chu C, Kotzin M, Xie J, Kaakati R, Berlin HP, Shadid H, Perry D, Pan M, Takiar R, Padalia K, Mills J, Meloche C, Bardwell A, Rochlen M, Blakely P, Leja M, Banerjee M, Riwes M, Magenau J, Anand S, Ghosh M, Pawarode A, Yanik G, Nathan S, Maciejewski J, Okwuosa T, Hayek SS. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors. JACC CardioOncol. 2023;5:821\u201332. https:\/\/doi.org\/10.1016\/j.jaccao.2023.07.007.","journal-title":"JACC CardioOncol"},{"key":"544_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","volume":"30","author":"JA Davis","year":"2024","unstructured":"Davis JA, Dima D, Ahmed N, DeJarnette S, McGuirk J, Jia X, Raza S, Khouri J, Valent J, Anwer F, Abdallah A-O, Hashmi H. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma. Transpl Cell Ther. 2024;30:298\u2013305. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.015.","journal-title":"Transpl Cell Ther"},{"key":"544_CR13","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1182\/blood-2025-8012","volume":"146","author":"H Mahadevia","year":"2025","unstructured":"Mahadevia H, Modi K, Shah R, Modi S, Vojjala N, Khumri T, Vodnala D, Cossor F. Incidence of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infections and cardiovascular events across different chimeric antigen receptor (CAR) T-cell therapy products in large B-cell lymphoma (DLBCL): A nationwide analysis. Blood. 2025;146:8012. https:\/\/doi.org\/10.1182\/blood-2025-8012.","journal-title":"Blood"},{"key":"544_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3324\/haematol.2022.280805","volume":"108","author":"M Kwon","year":"2023","unstructured":"Kwon M, Iacoboni G, Reguera JL, Corral LL, Morales RH, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Dom\u00ednguez MLG, Pina JMS, Mussetti A, Sancho JM, Bastos-Oreiro M, Catala E, Delgado J, Henriquez HL, Sanz J, Calbacho M, Bail\u00e9n R, Carpio C, Ribera JM, Sureda A, Briones J, Hernandez-Boluda JC, Cebri\u00e1n NM, Martin JLD, Mart\u00edn A, Barba P. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023;108:110\u201321. https:\/\/doi.org\/10.3324\/haematol.2022.280805.","journal-title":"Haematologica"},{"key":"544_CR15","doi-asserted-by":"publisher","first-page":"18696","DOI":"10.1038\/s41598-022-23589-9","volume":"12","author":"F Wada","year":"2022","unstructured":"Wada F, Jo T, Arai Y, Kitawaki T, Mizumoto C, Kanda J, Nishikori M, Yamashita K, Nagao M, Takaori-Kondo A. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy. Sci Rep. 2022;12:18696. https:\/\/doi.org\/10.1038\/s41598-022-23589-9.","journal-title":"Sci Rep"},{"key":"544_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjh.19117","volume":"203","author":"E Galli","year":"2023","unstructured":"Galli E, Bellesi S, Pansini I, Di Cesare G, Iacovelli C, Malafronte R, Maiolo E, Chiusolo P, Sica S, Sor\u00e0 F, Hohaus S. The CD4\/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity. Br J Haematol. 2023;203:564\u201370. https:\/\/doi.org\/10.1111\/bjh.19117.","journal-title":"Br J Haematol"},{"key":"544_CR17","doi-asserted-by":"publisher","first-page":"101161","DOI":"10.1016\/j.xcrm.2023.101161","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch M, Cazaux M, Cuffel A, Ruggiu M, Allain V, Corre B, Loe-Mie Y, Hosten B, Cisternino S, Auvity S, Thieblemont C, Caillat-Zucman S, Bousso P. A major role for CD4\u2009+\u2009T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep Med. 2023;4:101161. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101161.","journal-title":"Cell Rep Med"},{"key":"544_CR18","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1182\/bloodadvances.2024013146","volume":"8","author":"AC Lionel","year":"2024","unstructured":"Lionel AC, Neelapu SS. CAR T-cell expansion: harmful or helpful? Blood Adv. 2024;8:3311\u20133. https:\/\/doi.org\/10.1182\/bloodadvances.2024013146.","journal-title":"Blood Adv"},{"key":"544_CR19","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","volume":"78","author":"A Goldman","year":"2021","unstructured":"Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, Steingart RM, Mahmood SS, Schaffer WL, Perales M-A, Shouval R. Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. J Am Coll Cardiol. 2021;78:1800\u201313. https:\/\/doi.org\/10.1016\/j.jacc.2021.08.044.","journal-title":"J Am Coll Cardiol"},{"key":"544_CR20","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","volume":"41","author":"J L\u00f3pez-Send\u00f3n","year":"2020","unstructured":"L\u00f3pez-Send\u00f3n J, \u00c1lvarez-Ortega C, Zamora Au\u00f1on P, Bu\u00f1o Soto A, Lyon AR, Farmakis D, Cardinale D, Canales Albendea M, Feliu Batlle J, Rodr\u00edguez Rodr\u00edguez I, Rodr\u00edguez Fraga O, Albaladejo A, Mediavilla G, Gonz\u00e1lez-Juanatey JR, Mart\u00ednez Monzonis A, G\u00f3mez Prieto P, Gonz\u00e1lez-Costello J, Serrano Antol\u00edn JM, Cadenas Chamorro R, L\u00f3pez Fern\u00e1ndez T. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41:1720\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa006.","journal-title":"Eur Heart J"},{"key":"544_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jaccao.2023.10.008","volume":"6","author":"A Mecinaj","year":"2024","unstructured":"Mecinaj A, Gulati G, Ree AH, Gravdehaug B, R\u00f8sj\u00f8 H, Steine K, Wisl\u00f8ff T, Geisler J, Omland T, Heck SL. Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy-Related Cardiac Dysfunction. JACC CardioOncol. 2024;6:83\u201395. https:\/\/doi.org\/10.1016\/j.jaccao.2023.10.008.","journal-title":"JACC CardioOncol"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00544-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00544-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:17:03Z","timestamp":1785478623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00544-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00544-5","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved on November 1st, 2024, by the Ethics Committee of the Medical Faculty at Kiel University (D 610\/24). As this was a retrospective analysis of pseudonymized routinely collected data, the ethics committee waived the requirement for individual patient consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CDB received support for travel expenses and honoraria from Janssen, Amgen, Novartis, Jazz, BMS; DB received support for travel expenses by SERVIER and Janssen-Cilag. JCV received honoraria from AstraZeneca. OM received honoraria from Novartis, BMS and Pfizer, payment from the European Commission and holds a position as Board member of the German Society of Angiology - Society for Vascular Medicine.All other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"103"}}